Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects
✍ Scribed by J. Kewenter; S. Björk; Eva Haglind; L. Smith; J. Svanvik; C. Aåhrén
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 686 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
All inhabitants of the city of Goteborg who in 1982 were between 60 and 64 years of age (27,700) were randomly divided into a test and a control group. The 13,759 subjects in the test group were invited to perform Hemoccult I1 (Smith Kline Diagnostic, Sunnyvale, CA) fecal occult blood testing over 3 days and to repeat the testing after 16 to 22 months. At the first screening 9,040 (66%) completed the test, and 7,770 (58%) completed the test at the second screening. In the first screening the test group was divided into two subgroups in which the tests were rehydrated and unhydrated before development. All tests were rehydrated in the second screening; 1.9% and 5.8% of the tests were positive in the unhydrated and rehydrated subgroups, respectively. The number of diagnosed neoplasms in the first screening was significantly larger (P < 0.01) in the rehydrated group compared to the unhydrated group, 50 and 24 neoplasms, respectively. Sixteen of 61 carcinomas in the test group were found in the interval between the two screenings, 19 of the carcinomas at the second screening, and ten among the nonresponders. Rehydration of the Hemoccult I1 test is a necessity. Significantly more carcinomas (61) were found in the test group compared to the control group (20). There was a trend toward favorable tumor staging in the test group compared to the control group.
📜 SIMILAR VOLUMES
Our controlled trial of screening for colorectal cancer has now been in progress for almost five years. Screening is accomplished by rigid sigmoidoscopy in control and study groups and, in addition, by fecal occult blood testing in the study group. Patients screened are men and women age 40 and olde
positive tests will have colorectal neoplasia, including 5-10 per cent with cancer". Improvements in specificity using vegetable peroxidase inhibitors, faecal porphyrin assays, or immunochemical tests for blood should be possible. None of these tests will discriminate between bleeding from neoplasti
## Abstract Immunochemical fecal occult blood test (FIT) is a new colorectal cancer (CRC) screening method already recommended by the American screening guidelines. We aimed to test the feasibility of FIT as compared to guaiac fecal occult blood test (G‐FOBT) in a large urban population of Tel Aviv